MX2016001096A - Sales de dasatinib en forma amorfa. - Google Patents

Sales de dasatinib en forma amorfa.

Info

Publication number
MX2016001096A
MX2016001096A MX2016001096A MX2016001096A MX2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A
Authority
MX
Mexico
Prior art keywords
salts
dasatinib
amorphous form
relates
salt
Prior art date
Application number
MX2016001096A
Other languages
English (en)
Inventor
Martin Szelagiewicz
Fritz Blatter
Tiziana Chiodo
Andreas Hafner
Tobias Hintermann
Beate Salvador
Bernd Siebenhaar
Marcus Vossen
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2016001096A publication Critical patent/MX2016001096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención principalmente se refiere a sales de Dasatinib, en donde las sales están en forma amorfa. Las sales descritas en este documento comprenden un catión de un compuesto de fórmula 1 (ver Fórmula) y un anión de un segundo compuesto seleccionado del grupo que consiste en ácido glutárico, ácido nicotínico y sacarina. La invención se refiere en forma adicional a composiciones farmacéuticas que comprenden dicha sal. Además, la invención se refiere a procesos para preparar dichas sales. La invención se refiere a varios aspectos del uso de dicha sal o composición farmacéutica para tratar una enfermedad.
MX2016001096A 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa. MX2016001096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178015 2013-07-25
PCT/EP2014/065674 WO2015011119A2 (en) 2013-07-25 2014-07-22 Salts of dasatinib in amorphous form

Publications (1)

Publication Number Publication Date
MX2016001096A true MX2016001096A (es) 2016-04-25

Family

ID=48832837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001096A MX2016001096A (es) 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa.

Country Status (10)

Country Link
US (1) US9884857B2 (es)
EP (1) EP3024831A2 (es)
JP (1) JP6370377B2 (es)
KR (1) KR101831535B1 (es)
CN (1) CN105377842A (es)
AU (1) AU2014295143B9 (es)
CA (1) CA2917209A1 (es)
MX (1) MX2016001096A (es)
RU (1) RU2655435C2 (es)
WO (1) WO2015011119A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053436B2 (en) 2014-07-08 2018-08-21 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
EP3294700B1 (en) 2015-05-08 2020-01-29 BASF Agro B.V. A process for the preparation of limonene-4-ol
DK3294720T3 (da) 2015-05-08 2021-02-15 Basf Agro Bv Fremgangsmåde til fremstilling af terpinolenepoxid
MX2018015764A (es) 2016-06-15 2019-08-29 Basf Agro Bv Proceso para la epoxidacion de un alqueno tetrasustituido.
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
CN107501305B (zh) * 2017-09-26 2019-04-05 玉林师范学院 一种达沙替尼-铜(ii)配合物及其合成方法和应用
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
MX2022012248A (es) * 2020-03-30 2022-10-27 Igia Pharmaceuticals Inc Formulacion pediatrica de inhibidores de tirosina quinasa.
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
WO2024186765A1 (en) * 2023-03-03 2024-09-12 Aems Corp. Amorphous solid composition, methods and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (en) 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
PL2508523T5 (pl) 2007-10-23 2020-08-10 Teva Pharmaceutical Industries Ltd. Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
CN103764632B (zh) 2011-08-30 2017-05-17 巴斯夫欧洲公司 环丙嘧啶和二噻农的共晶
US9199997B2 (en) * 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
CN102429880B (zh) * 2011-11-29 2014-10-15 上海创诺制药有限公司 一种达沙替尼片
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
CA2876539A1 (en) 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US9290452B2 (en) 2012-08-06 2016-03-22 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US20150333124A1 (en) 2012-12-20 2015-11-19 Basf Se Edge halogenation of graphene materials
BR112015020194A2 (pt) 2013-03-07 2017-07-18 Basf Se co-cristais, processo para a preparação dos co-cristais, formulação agrícola, métodos para controle de pragas, para melhoria da saúde das plantas e para a proteção de material de propagação de planta contra pragas e material de propagação de planta

Also Published As

Publication number Publication date
KR101831535B1 (ko) 2018-02-22
CA2917209A1 (en) 2015-01-29
JP2016525528A (ja) 2016-08-25
AU2014295143B9 (en) 2017-03-23
JP6370377B2 (ja) 2018-08-08
EP3024831A2 (en) 2016-06-01
WO2015011119A3 (en) 2015-05-28
AU2014295143A1 (en) 2016-02-11
US9884857B2 (en) 2018-02-06
US20160168142A1 (en) 2016-06-16
RU2655435C2 (ru) 2018-05-29
WO2015011119A2 (en) 2015-01-29
KR20160025573A (ko) 2016-03-08
CN105377842A (zh) 2016-03-02
AU2014295143B2 (en) 2017-03-16
RU2016106124A (ru) 2017-08-30

Similar Documents

Publication Publication Date Title
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2016001095A (es) Sales de dasatinib en forma cristalina.
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2014153203A3 (en) Alkyl-amine harmine derivatives for promoting bone growth
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
PH12019500822A1 (en) Crystalline forms of eravacycline
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2015042414A8 (en) Multicyclic compounds and methods of using same
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
UA111334C2 (uk) Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить
WO2015107553A3 (en) A process for the preparation of crizotinib or an acid addition salt thereof